MedTrace Logo

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

NCT00561951 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 951

Last updated 2011-07-14

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.

Conditions

Interventions

DRUG

fesoterodine fumarate

8mg tablets OD for 12 weeks

DRUG

Placebo

Corresponding placebo tablets OD for 12 weeks

DRUG

fesoterodine fumarate

4mg tablets OD for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Hong Kong
  • Japan
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561951 on ClinicalTrials.gov